Efficacy of Teriparatide on pelvic fracture healing, finds S
A Study was conducted to determine how teriparatide (20 microg/day; TPTD) results in improved radiologic healing, reduced pain, and improved functional outcome vs placebo over 3 months in pelvic fracture patients.

This randomized, placebo-controlled study enrolled 35 patients within 4 weeks of pelvic fracture and evaluated the effect of blinded TPTD vs placebo over 3 months on fracture healing. Fracture healing from CT images at 0 and 3 months was assessed as cortical bridging using a 5-point scale. The numeric rating scale (NRS) for pain was administered monthly.

--The mean age was 82, and more than 80% were female. The intention to treat analysis showed no group difference in cortical bridging score, and 50% of fractures in TPTD-treated and 53% of fractures in placebo-treated patients were healed at 3 months, unchanged after adjustment for age, sacral fracture, and fracture displacement.

--Median pain score dropped significantly in both groups with no group differences.

--Both CSPPS and Timed Up and Go (TUG) test improved in the teriparatide group, whereas there was no improvement in the placebo group.

In conclusion, there was no difference in radiographic healing (CT at 3 months) or discomfort with TPTD versus placebo; however, TPTD-treated participants had better physical performance than the placebo group.

Source: https://link.springer.com/article/10.1007/s00198-021-06065-4